D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today ...

Researchers identify bone-forming cells as the driver of scoliosis caused by a genetic disorder, which can be prevented ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people.

Pasithea Therapeutics Corp. (NASDAQ: KTTA) ('Pasithea” or the 'Company”), a clinical-stage biotechnology company developing ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ...

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...

The Wall Street Journal report added that Revolution Medicines would bolster AbbVie's efforts to build its presence in the ...

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Gastric cancer cells can activate KRAS-driven signals, enabling autonomous tumor growth by producing their own WNT proteins. New research reveals how gastric cancer cells exploit WNT signaling for ...